Evidence map›Paper›PMID 42881436›Full record

ArticleBMC emergency medicine2026

Early serial changes in FIB-4 after out-of-hospital cardiac arrest and short-term clinical outcomes: a retrospective cohort study.

Muhammed Emin Zora, Ömer Sert

Abstract read
In one paragraph

Article in BMC emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Muhammed Emin ZoraDepartment of Anesthesiology and Reanimation, Uşak University Faculty of Medicine, Uşak, Türkiye. muhammedeminzora@hotmail.com.ORCID http://orcid.org/0000-0001-7919-3578
Ömer SertAnesthesiology and Reanimation Clinic, Uşak Training and Research Hospital, Uşak, Türkiye.ORCID http://orcid.org/0000-0002-5189-0029

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Fibrosis-4 (FIB-4) index combines age, aminotransferase levels, and platelet count. Although developed for chronic liver fibrosis, its components may reflect acute hepatic and systemic injury after cardiac arrest. The primary aim of this study was to characterize early changes in FIB-4 from admission to an approximately 72-hour repeat assessment after out-of-hospital cardiac arrest (OHCA). Secondarily, we evaluated the association of FIB-4 values with 28-day mortality and whether repeat measurement provided additional prognostic information.

methodsThis single-center retrospective cohort study included adults admitted to the intensive care unit after sustained return of spontaneous circulation between May 1, 2023, and May 1, 2026. After a record-level eligibility audit, 188 patients were included; 28-day vital status was available for 182. FIB-4 was calculated from the first laboratory set obtained at intensive care unit admission and from the complete laboratory set closest to 72 h after the admission laboratory sample within a 48-96-hour window. The primary analysis assessed paired change in FIB-4. Secondary analyses examined the association of admission FIB-4 with 28-day mortality and, using a 72-hour landmark approach, the association of repeat FIB-4 with subsequent mortality through day 28 and its incremental contribution beyond the admission value.

resultsA valid repeat FIB-4 measurement was available in 122 patients. In paired analysis, median FIB-4 decreased from 5.21 at admission to 3.16 at approximately 72 h (p < 0.001). Of the 182 patients with known 28-day vital status, 82 died (45.1%). Admission FIB-4 was higher in patients who died than in survivors (6.84 [3.25-10.75] vs. 4.14 [2.32-8.16]; p = 0.019). Each doubling of admission FIB-4 was associated with higher odds of mortality in the unadjusted analysis (OR, 1.26; 95% CI, 1.02-1.55; p = 0.029); however, in the OHCA-specific complete-case model, the adjusted association was not statistically significant (OR, 1.16; 95% CI, 0.91-1.46; p = 0.227), and adding FIB-4 to the clinical model increased the AUC only from 0.647 to 0.648 (difference, 0.001). In the 72-hour landmark cohort, 56 patients had an available pre-landmark repeat measurement and known 28-day vital status; 29 died after the landmark. Repeat FIB-4 showed weak discrimination for subsequent mortality (AUC, 0.585), and the OR per doubling was 1.23 (95% CI, 0.86-1.76; p = 0.255). Adding repeat FIB-4 to the admission value increased the AUC from 0.575 to 0.581 (difference, 0.006; 95% CI, - 0.053 to 0.205; likelihood-ratio p = 0.294).

conclusionsAmong patients with available paired measurements, FIB-4 decreased from admission to the approximately 72-hour repeat assessment; however, the magnitude of change showed little discriminatory ability for subsequent mortality in the landmark cohort. Higher admission FIB-4 was associated with mortality in the unadjusted analysis, but this association was not statistically significant after adjustment for major OHCA-specific prognostic factors, and FIB-4 provided essentially no incremental discrimination when added to the clinical model. The incremental prognostic contribution of repeat measurement remained uncertain because of the limited landmark sample and imprecise estimates. FIB-4 should be regarded as a research marker of the acute systemic and hepatic response after cardiac arrest rather than as a stand-alone clinical prediction tool.

Indexed as

Out-of-Hospital Cardiac ArrestAgedBiomarkersFemaleHumansIntensive Care UnitsMaleMiddle AgedPlatelet CountPrognosisRetrospective StudiesBiomarkersBiomarkersFibrosis-4 indexIntensive care unitsOut-of-hospital cardiac arrestPost-cardiac arrest syndrome

Identifiers

PMID42881436
PMCPMC13673793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.